Amyloid Remains a Key Target in Next-Generation Alzheimer’s Treatments

Brain and Pills_Taylor Tieden for BioSpace

Pictured: A colorful brain surrounded by pill bottles/Taylor Tieden for BioSpace

With 164 clinical trials assessing 127 drugs in the pipeline, momentum in the Alzheimer’s space is on an upward swing—and while the field has expanded from its initial targets of amyloid beta and tau, experts believe they will remain a pivotal part of the treatment landscape.

Five or 10 years ago, 75% of the drugs in development for Alzheimer’s were anti-amyloid beta (Aβ) or anti-tau drugs, said Howard Fillit, co-founder and chief science officer of the Alzheimer’s Drug Discovery Foundation. “Today that’s completely reversed, as 75% of the drugs in clinical development are non-amyloid, non-tau drugs,” Fillit told BioSpace.

The framework for new approaches coming down the pipeline is to confront the leading risk factor for Alzheimer’s disease: age. The majority of clinical development aims to address age-related issues…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks